Study examining the effects of gut microbiota on tumor suppressive efficacy of trastuzumab in HER2-positive breast cancer revealed that antibiotic exposure or FMT from antibiotic-treated mice greatly impair the antitumor activity of trastuzumab (122). This evidence concerns the gene ERBB2 and breast carcinoma.